Researchers report on the BRIGHT AML 1019 Phase III trial.
Naveed Saleh, MD, MS
Researchers explore the predictive capability of EVI1 expression.
Genetic profiles of thyroid cancer shed light on molecular mechanisms.
Researchers look at how mutation status can influence responses to targeted therapy in thyroid cancer.
Investigators assessed effects of TIB on cell number, migration, invasion, estrogen, and progesterone receptor activity and content.
Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care.
Prognostic signature associated with AML relapse risk potential harbors gene subsets that apply to only certain patient subgroups.
In this study, FLT3-IRAK1/4 inhibitor (NCGC1481) removed adaptively resistant FLT3-mutant AML cells.
Age disparities in oncology trials are continuing, despite opposition to this issue.
Video-assisted thoracic surgery (VATS) results in fewer in-hospital complications and a shorter length of stay compared with open surgery in patients with early-stage lung cancer.